



# European Cancer Patient Coalition

**IQN Path, ECPC and EFPIA present:**

**Unlocking the Potential of Precision Medicine in Europe**



**Tuesday, 23 February from 14.30 to 15.45 CET | Virtual event**

The International Quality Network for Pathology ([IQN Path](#)), the European Cancer Patient Coalition ([ECPC](#)) and the European Federation of Pharmaceutical Industries and Associations ([EFPIA](#)) will jointly share the findings from the study “**Unlocking the potential of precision medicine in Europe – Improving cancer care through broader access to quality biomarker testing**”.

**REGISTER HERE**

**Join us to discuss how to improve cancer care through broader access to quality biomarker testing**

IQN Path, ECPC and EFPIA have assessed biomarkers' access and quality across Europe (27 EU Member States and the UK) and generated a biomarker access and quality scorecard for each of these countries. The collected data have helped map the ideal pathway for the uptake and use of biomarkers and identify common gaps across countries. Based on this analysis, IQN Path,

## Draft agenda

Welcome by **Nicola Normanno**, Principal Investigator of the project and IQN Path President

Presentation of the data by **L.E.K. Consulting**

Q&A with the organisers, led by the moderator **Vivek Muthu**, Health systems Consultant & former Global Head of Healthcare, Economist Intelligence Unit

- **IQN Path: Nicola Normanno**, President
- **ECPC: Kathi Apostolidis**, Board Member
- **EFPIA: Marlene Thomas**, EFPIA Precision Medicine Working Group and Roche

## Panel discussion & Q&A

- **European Society for Medical Oncology (ESMO): Rosa Giuliani**, Director of Public Policy and Board Member
- **European Society of Pathology: Holger Moch**, President
- **Member of the European Parliament:** Name to be announced
- **EUnetHTA/national payer:** Name to be announced

**REGISTER HERE**

*This event is free of charge.*

### **ABOUT IQN PATH**

[IQN Path](#) is an international multi-stakeholder expert group focused on improving quality of clinical biomarker testing, bringing together organisations and key stakeholders involved in quality implementation of biomarker testing in pathology globally.

### **ABOUT ECPC**

[European Cancer Patient Coalition](#) is the voice of cancer patients in Europe. With over 450 members, ECPC is Europe's largest umbrella cancer patients' association, covering all 27 EU member states and many other European and non-European countries. ECPC represents patients affected by all types of cancers, from the most common to the rarest.

### **ABOUT EFPIA**

The European Federation of Pharmaceutical Industries and Associations ([EFPIA](#)) represents the biopharmaceutical industry operating in Europe. Through its direct membership of 36 national associations, 39 leading pharmaceutical companies and a growing number of small and medium-sized enterprises (SMEs), EFPIA's mission is to create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy.

Subscribe

Past Issues

Translate ▼



Copyright © 2020 European Cancer Patient Coalition, All rights reserved.

You are receiving this email because you are a partner of ECPC.

**Our mailing address is:**

European Cancer Patient Coalition  
Rue Montoyer 40  
Brussels 1000  
Belgium

[Add us to your address book](#)

Want to change how you receive these emails?

You can [update your preferences](#) or **[unsubscribe from this list](#)**.

This email was sent to <<Email Address>>

[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)  
European Cancer Patient Coalition · Rue Montoyer 40 · Brussels 1000 · Belgium